Fortress Biotech, Inc. (FBIO) Analyse boursière

Présentation de l'entreprise

Fortress Biotech, Inc. (FBIO) operates as a biopharmaceutical company dedicated to the development and commercialization of specialized biopharmaceutical products within the healthcare sector. The firm focuses specifically on the biotechnology industry, a field characterized by high research and development costs and the potential for significant innovation in treating specific medical conditions. As a market capitalization of 74.39 millions of dollars, the company represents a mid-to-small cap entity with a trailing twelve-month revenue of 63.26 millions of dollars, while the number of employees remains unlisted in available data. These valuation metrics and revenue figures indicate that Fortress Biotech holds a niche position in the dermatology space, commercializing products such as Emrosi for rosacea treatment and Qbrexza, a medicated clotrimazole formulation. The company's scale suggests it is leveraging a focused product portfolio rather than a broad diversification, which is typical for early-stage to growth-phase biotechnology firms aiming to establish market share in specialized therapeutic areas.

Santé financière

The financial statements for the trailing twelve months reveal a revenue of 63.26 millions of dollars against a net income loss of 1.882 millions of dollars, highlighting a significant gap between top-line growth and bottom-line profitability. This divergence indicates that the company's cost structure, including operating expenses and research expenditures, currently exceeds its earnings from sales operations. The entity reported an EBITDA of negative 65.56 millions of dollars, reflecting substantial cash burn typical of the development phase before products achieve full commercial maturity. Free cash flow stood at negative 47.286376 millions of dollars, signaling that the company is consuming cash reserves to fund its operations and product development rather than generating surplus liquidity. Margin analysis shows a gross margin of 48.1%, which suggests reasonable efficiency in production and cost of goods sold, yet this is offset by an operating margin of negative 29.8% and a reported profit margin figure of 10.8% in the provided data. The balance sheet displays a cash position of 79.38 millions of dollars against total debt of 67.22 millions of dollars, resulting in a debt-to-equity ratio of 108.09, which implies a highly leveraged capital structure relative to equity. Despite the high leverage, the current ratio of 2.49 indicates strong short-term liquidity, as current assets are more than double current liabilities. Return on equity is negative 108.7% and return on assets is negative 26.6%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than positive returns.

Évaluation de la valorisation

The valuation metrics present a challenging picture for traditional equity analysis, with a P/E ratio (TTM) listed as N/A due to negative earnings and a forward P/E of negative 1.31. The discrepancy between the trailing and forward P/E ratios implies that the market expects a significant turnaround in earnings trajectory to achieve positive profitability in the future. Fortress Biotech trades at a price-to-book ratio of 1.28, indicating that the market values the company at a slight premium over its net asset book value despite the absence of current earnings. Alternative valuation metrics such as a price-to-sales ratio of 1.18 and an EV/EBITDA of negative 1.14 suggest that investors are pricing the stock based on future revenue potential and asset value rather than current earnings power. The stock's price range over the past year has fluctuated between a 52-week high of 4.53 dollars and a 52-week low of 1.33 dollars. While the specific current trading price is not provided in the source data, the valuation metrics suggest the stock is priced in a range that reflects high risk and high reward expectations associated with biotechnology development. The beta of 1.45 indicates that the stock exhibits price volatility that is significantly higher than the broader market, moving 45% more volatile than the market index on average.

Growth & Income

The company demonstrates a revenue growth rate of 6.3% year-over-year, whereas earnings growth is N/A due to the lack of positive net income in the reporting period. The disparity between positive revenue growth and negative earnings growth implies that the company is successfully expanding its sales volume but is unable to convert this growth into net profit due to high operating costs. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, Fortress Biotech retains all of its earnings to reinvest directly into research, development, and commercialization efforts rather than distributing income to shareholders. This reinvestment strategy is standard for biotechnology companies in the development phase, where capital allocation toward product pipelines is prioritized over shareholder payouts. The overall growth and income profile of Fortress Biotech is defined by revenue expansion without current profitability, relying on cash reserves to fund operations while seeking to achieve sustainable earnings in the future.